Off-the-shelf CAR-T therapy induces remission in child with ALL

Paid access only, http://www.nature.com/nbt/journal/v34/n1/full/nbt0116-12.html

The impressive response seen in the first leukemia patient treated using donor T cells genetically modified to target the CD19 antigen on tumor cells may signal the opening of a new chapter in the race to commercialize T cell–based chimeric antigen receptor (CAR-T) technologies. A formal clinical trial has yet to commence using the tr…